Cargando…
Why we should all be more careful in drawing conclusions about how COVID-19 is changing drug markets
Autor principal: | Giommoni, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332913/ https://www.ncbi.nlm.nih.gov/pubmed/32646713 http://dx.doi.org/10.1016/j.drugpo.2020.102834 |
Ejemplares similares
-
How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?
por: Gou, Yang, et al.
Publicado: (2023) -
Why Reducing Low-Value Care Fails to Bend the Cost Curve, and Why We Should Do it Anyway
por: Kroon, Daniëlle, et al.
Publicado: (2023) -
The care of infants with rapid weight gain: Should we be doing more?
por: Fangupo, Louise, et al.
Publicado: (2022) -
Undergraduate medical education; how far should we go?
por: Benamer, Hani TS
Publicado: (2007) -
Atherosclerotic renal artery stenosis: how should we do?
por: Jiang, Ying, et al.
Publicado: (2021)